{"id":69878,"date":"2026-07-14T13:44:44","date_gmt":"2026-07-14T05:44:44","guid":{"rendered":"https:\/\/flcube.com\/?p=69878"},"modified":"2026-07-14T13:44:45","modified_gmt":"2026-07-14T05:44:45","slug":"shenyang-xingqi-pharmaceutical-secures-nmpa-approval-for-sq-23101-injection-novel-bispecific-antibody-therapy-for-thyroid-eye-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69878","title":{"rendered":"Shenyang Xingqi Pharmaceutical Secures NMPA Approval for SQ-23101 Injection \u2013 Novel Bispecific Antibody Therapy for Thyroid Eye Disease"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shenyang Xingqi Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/300573:SHE\">SHE: 300573<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has granted approval to initiate <strong>clinical trials<\/strong> for its <strong>SQ-23101 injection<\/strong>, a <strong>Category 1 therapeutic biological product<\/strong> indicated for the treatment of <strong>thyroid eye disease<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial authorization, Category 1 innovative biologic<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SQ-23101 injection (recombinant humanized IgG bispecific antibody)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Treatment of thyroid eye disease<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>14 Jul 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Phase I clinical trials to evaluate safety, tolerability, and preliminary efficacy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Recombinant humanized IgG bispecific antibody<\/li>\n\n\n\n<li><strong>Classification:<\/strong> Category 1 therapeutic biological product (China&#8217;s highest innovation tier)<\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Novel bispecific design targeting multiple inflammatory pathways involved in thyroid eye disease pathogenesis<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Proprietary technology developed by Shenyang Xingqi Pharmaceutical<\/li>\n\n\n\n<li><strong>Preclinical Data:<\/strong> Demonstrated favorable safety profile and significant clinical development value<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-development-pathway\" class=\"wp-block-heading\">Clinical Development Pathway<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Stage<\/th><th>Status<\/th><th>Key Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Preclinical Studies<\/strong><\/td><td>Completed<\/td><td>Established safety profile and therapeutic potential<\/td><\/tr><tr><td><strong>IND Submission<\/strong><\/td><td>Approved<\/td><td>NMPA clearance for human trials<\/td><\/tr><tr><td><strong>Phase I Trial<\/strong><\/td><td>Pending initiation<\/td><td>Assess safety, tolerability, pharmacokinetics in healthy volunteers<\/td><\/tr><tr><td><strong>Phase II Trial<\/strong><\/td><td>Not yet initiated<\/td><td>Evaluate efficacy and optimal dosing in thyroid eye disease patients<\/td><\/tr><tr><td><strong>Phase III Trial<\/strong><\/td><td>Not yet initiated<\/td><td>Confirm efficacy and monitor adverse reactions in larger patient population<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Thyroid eye disease, also known as Graves&#8217; ophthalmopathy, is an autoimmune condition characterized by inflammation and tissue remodeling in the orbit, leading to proptosis, diplopia, and potential vision loss. Current treatment options remain limited, creating substantial unmet medical need.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Disease Burden:<\/strong> Thyroid eye disease affects approximately 16 out of every 100,000 women and 3 out of every 100,000 men globally, with higher prevalence in regions with iodine deficiency.<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Few targeted therapies exist for thyroid eye disease; most treatments focus on symptom management rather than addressing underlying pathophysiology.<\/li>\n\n\n\n<li><strong>Commercial Potential:<\/strong> As a Category 1 innovative biologic with novel mechanism of action, SQ-23101 could command premium pricing if clinical trials confirm efficacy.<\/li>\n\n\n\n<li><strong>Strategic Positioning:<\/strong> This development positions Shenyang Xingqi among China&#8217;s growing cohort of biopharmaceutical innovators developing specialized biologics for autoimmune conditions.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory approvals, and commercial expectations for SQ-23101. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u5174\u9f50\u773c\u836f\uff1a\u5173\u4e8eSQ-23101\u6ce8\u5c04\u6db2\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u5174\u9f50\u773c\u836f\uff1a\u5173\u4e8eSQ-23101\u6ce8\u5c04\u6db2\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-8ef466bd-ba13-43d2-811c-93eaa1ad8a69\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u5174\u9f50\u773c\u836f\uff1a\u5173\u4e8eSQ-23101\u6ce8\u5c04\u6db2\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\">\u5174\u9f50\u773c\u836f\uff1a\u5173\u4e8eSQ-23101\u6ce8\u5c04\u6db2\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/\u5174\u9f50\u773c\u836f\uff1a\u5173\u4e8eSQ-23101\u6ce8\u5c04\u6db2\u83b7\u5f97\u4e34\u5e8a\u8bd5\u9a8c\u6279\u51c6\u901a\u77e5\u4e66\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8ef466bd-ba13-43d2-811c-93eaa1ad8a69\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced that China&#8217;s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[1231,3708],"class_list":["post-69878","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-she-300573","tag-xingqi-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shenyang Xingqi Pharmaceutical Secures NMPA Approval for SQ-23101 Injection \u2013 Novel Bispecific Antibody Therapy for Thyroid Eye Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced that China&#039;s National Medical Products Administration (NMPA) has granted approval to initiate clinical trials for its SQ-23101 injection, a Category 1 therapeutic biological product indicated for the treatment of thyroid eye disease.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69878\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shenyang Xingqi Pharmaceutical Secures NMPA Approval for SQ-23101 Injection \u2013 Novel Bispecific Antibody Therapy for Thyroid Eye Disease\" \/>\n<meta property=\"og:description\" content=\"Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced that China&#039;s National Medical Products Administration (NMPA) has granted approval to initiate clinical trials for its SQ-23101 injection, a Category 1 therapeutic biological product indicated for the treatment of thyroid eye disease.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69878\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-14T05:44:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-14T05:44:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69878#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69878\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shenyang Xingqi Pharmaceutical Secures NMPA Approval for SQ-23101 Injection \u2013 Novel Bispecific Antibody Therapy for Thyroid Eye Disease\",\"datePublished\":\"2026-07-14T05:44:44+00:00\",\"dateModified\":\"2026-07-14T05:44:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69878\"},\"wordCount\":399,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"SHE: 300573\",\"Xingqi Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69878#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69878\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69878\",\"name\":\"Shenyang Xingqi Pharmaceutical Secures NMPA Approval for SQ-23101 Injection \u2013 Novel Bispecific Antibody Therapy for Thyroid Eye Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-14T05:44:44+00:00\",\"dateModified\":\"2026-07-14T05:44:45+00:00\",\"description\":\"Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced that China's National Medical Products Administration (NMPA) has granted approval to initiate clinical trials for its SQ-23101 injection, a Category 1 therapeutic biological product indicated for the treatment of thyroid eye disease.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69878#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69878\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69878#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shenyang Xingqi Pharmaceutical Secures NMPA Approval for SQ-23101 Injection \u2013 Novel Bispecific Antibody Therapy for Thyroid Eye Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shenyang Xingqi Pharmaceutical Secures NMPA Approval for SQ-23101 Injection \u2013 Novel Bispecific Antibody Therapy for Thyroid Eye Disease - Insight, China&#039;s Pharmaceutical Industry","description":"Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced that China's National Medical Products Administration (NMPA) has granted approval to initiate clinical trials for its SQ-23101 injection, a Category 1 therapeutic biological product indicated for the treatment of thyroid eye disease.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69878","og_locale":"en_US","og_type":"article","og_title":"Shenyang Xingqi Pharmaceutical Secures NMPA Approval for SQ-23101 Injection \u2013 Novel Bispecific Antibody Therapy for Thyroid Eye Disease","og_description":"Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced that China's National Medical Products Administration (NMPA) has granted approval to initiate clinical trials for its SQ-23101 injection, a Category 1 therapeutic biological product indicated for the treatment of thyroid eye disease.","og_url":"https:\/\/flcube.com\/?p=69878","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-14T05:44:44+00:00","article_modified_time":"2026-07-14T05:44:45+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69878#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69878"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shenyang Xingqi Pharmaceutical Secures NMPA Approval for SQ-23101 Injection \u2013 Novel Bispecific Antibody Therapy for Thyroid Eye Disease","datePublished":"2026-07-14T05:44:44+00:00","dateModified":"2026-07-14T05:44:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69878"},"wordCount":399,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["SHE: 300573","Xingqi Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69878#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69878","url":"https:\/\/flcube.com\/?p=69878","name":"Shenyang Xingqi Pharmaceutical Secures NMPA Approval for SQ-23101 Injection \u2013 Novel Bispecific Antibody Therapy for Thyroid Eye Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-14T05:44:44+00:00","dateModified":"2026-07-14T05:44:45+00:00","description":"Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced that China's National Medical Products Administration (NMPA) has granted approval to initiate clinical trials for its SQ-23101 injection, a Category 1 therapeutic biological product indicated for the treatment of thyroid eye disease.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69878#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69878"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69878#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shenyang Xingqi Pharmaceutical Secures NMPA Approval for SQ-23101 Injection \u2013 Novel Bispecific Antibody Therapy for Thyroid Eye Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69878"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69878\/revisions"}],"predecessor-version":[{"id":69918,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69878\/revisions\/69918"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}